2 Reasons I'm Keeping My Eye on Eli Lilly Stock Right Now

Key Points Eli Lilly is dominating the large and rapidly growing incretin analog market in the U.S. with its GLP-1 drug, tirzepatide. Its investigational oral GLP-1 drug, orforglipron, could significantly expand its target addressable market. The company also has a strong presence in therapeutic areas such as oncology, immunology, and neuroscience. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) has reported an impressive performance for the third quarter, with both revenues and ea ...